Stock page
Brookline Capital Acquisition Corp II (BCACU)
Xynomic Pharmaceuticals Holdings Inc is a biopharmaceutical company which focuses on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. The company aims to build a clinical and pre-clinical stage oncology pipeline targeting cancers.
Quote snapshot
$10.50
Daily change: —
ExchangeNAS
Updated2026-05-09T04:33:11.377331Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|